Hope is in bloom in RET + NSCLC
Targeted therapies for biomarkers like ALK, BRAF, EGFR, HER2 (ERBB2 mutation), KRAS G12C, MET, NTRK, RET, and ROS1 are available.1,2 That’s why it’s important to:
- Identify biomarkers with broad molecular testing like next-generation sequencing (NGS)3
- If clinically appropriate, wait for test results to confirm treatment3,4
Identify what drives disease to help confirm your treatment course.
Expert insights: an overview of biomarker testing in metastatic NSCLC with Dr. Timothy Burns, medical oncologist at UPMC Hillman Cancer Center
RET in
NSCLC
Molecular
testing
Questions?
- *The NCCN Guidelines® for NSCLC provide recommendations for individual biomarkers that should be tested and recommend testing techniques, but do not endorse any specific commercially available biomarker assays or commercial laboratories.
- †The NCCN Guidelines recommend molecular testing and strongly advise broader molecular profiling in eligible patients with metastatic NSCLC, with the goal of identifying rare driver mutations for which effective drugs may already be available or to appropriately counsel patients regarding the availability of clinical trials.
- NCCN makes no warranties of any kind whatsoever regarding their content, use, or application, and disclaims any responsibility for their application or use in any way.
- ALK=anaplastic lymphoma kinase; BRAF=B-Raf proto-oncogene; EGFR=epidermal growth factor receptor; ERBB2=erb-b2 receptor tyrosine kinase 2; HER2=human epidermal growth factor receptor 2; KRAS=Kirsten rat sarcoma; MET=MET proto-oncogene; NCCN=National Comprehensive Cancer Network® (NCCN®); NSCLC=non–small cell lung cancer; NTRK=neurotrophic tyrosine receptor kinase; RET=rearranged during transfection; ROS1=ROS proto-oncogene 1.
References: 1. VanderLaan PA, Rangachari D, Costa DB. The rapidly evolving landscape of biomarker testing in non–small cell lung cancer. Cancer Cytopathol. 2021;129(3):179-181. 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.3.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed April 18, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. 3. Kato S, Subbiah V, Marchlik E, Elkin SK, Carter JL, Kurzrock R. RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients. Clin Cancer Res. 2017;23(8):1988-1997. 4. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998-2006.